Clinical Read2026-09-30

CT-95 (mesothelin)

Context Therapeutics Inc.CNTX
Indication
Solid tumors
Stage
phase1
Event
Initial Data
Details

May 6, 2026: Context Therapeutics Inc. (NASDAQ: CNTX) reported Q1 2026 financial results and outlined upcoming pipeline catalysts for its T cell engaging bispecific antibodies in solid tumors.

  • CTIM-76 (CLDN6 x CD3; platinum-resistant ovarian cancer): In April 2026, FDA granted Fast Track Designation for patients who have received all standard-of-care therapies. Phase 1a interim clinical data are expected in June 2026 and are anticipated to include preliminary safety, efficacy, and correlative results.

  • CT-95 (MSLN x CD3): Phase 1a clinical data are expected in September 2026.

  • CT-202 (Nectin-4 x CD3): Presented preclinical data at the AACR Annual Meeting 2026. Received HREC approval and CTN acknowledgement by Australia’s TGA to initiate a first-in-human Phase 1 trial; Phase 1 initiation (first patient dosing) is expected in Q3 2026.

Financials: Cash and cash equivalents were $54.5 million as of March 31, 2026 (vs. $66.0 million at Dec. 31, 2025), expected to fund operations into mid-2027. Net loss was $8.7 million for Q1 2026.